320 related articles for article (PubMed ID: 29414661)
1. Fine tuning subsets of CD4
Zhao Z; Zhang X; Su L; Xu L; Zheng Y; Sun J
Int Immunopharmacol; 2018 Mar; 56():269-276. PubMed ID: 29414661
[TBL] [Abstract][Full Text] [Related]
2. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
[TBL] [Abstract][Full Text] [Related]
3. New Molecular and Cellular Mechanisms of Tolerance: Tolerogenic Actions of IL-2.
Pérol L; Piaggio E
Methods Mol Biol; 2016; 1371():11-28. PubMed ID: 26530792
[TBL] [Abstract][Full Text] [Related]
4. Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.
Ballesteros-Tato A
Immunotherapy; 2014; 6(11):1207-20. PubMed ID: 25496335
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cells overexpressing IL-35 effectively inhibit CD4
Zhao N; Li H; Yan Y; Jiang R; He X
Cell Immunol; 2017 Feb; 312():61-66. PubMed ID: 27993351
[TBL] [Abstract][Full Text] [Related]
6. Low-dose IL-2 therapy in autoimmune diseases: An update review.
Zhang R; Zhao Y; Chen X; Zhuang Z; Li X; Shen E
Int Rev Immunol; 2024 May; 43(3):113-137. PubMed ID: 37882232
[TBL] [Abstract][Full Text] [Related]
7. Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases.
Horwitz DA; Bickerton S; La Cava A
Front Immunol; 2021; 12():681062. PubMed ID: 34211471
[TBL] [Abstract][Full Text] [Related]
8. Restoring regulation - IL-2 therapy in systemic lupus erythematosus.
Humrich JY; Riemekasten G
Expert Rev Clin Immunol; 2016 Nov; 12(11):1153-1160. PubMed ID: 27283871
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of interleukin-2 in autoimmune diseases.
Yuan Y; Kolios AGA; Liu Y; Zhang B; Li H; Tsokos GC; Zhang X
Trends Mol Med; 2022 Jul; 28(7):596-612. PubMed ID: 35624009
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 and autoimmune disease occurrence and therapy.
Geng X; Zhang R; Yang G; Jiang W; Xu C
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(11):1462-7. PubMed ID: 23111957
[TBL] [Abstract][Full Text] [Related]
11. Treg and lupus.
Bonelli M; Smolen JS; Scheinecker C
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i65-66. PubMed ID: 19995748
[TBL] [Abstract][Full Text] [Related]
12. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.
Sharabi A; Lapter S; Mozes E
J Autoimmun; 2010 Mar; 34(2):87-95. PubMed ID: 19596183
[TBL] [Abstract][Full Text] [Related]
13. TGF-β1-induced regulatory T cells.
Hadaschik EN; Enk AH
Hum Immunol; 2015 Aug; 76(8):561-4. PubMed ID: 26116540
[TBL] [Abstract][Full Text] [Related]
14. T-cell-based immunotherapy of autoimmune diseases.
Ulivieri C; Baldari CT
Expert Rev Vaccines; 2013 Mar; 12(3):297-310. PubMed ID: 23496669
[TBL] [Abstract][Full Text] [Related]
15. Regulatory Role of CD4
Vdovenko D; Eriksson U
J Immunol Res; 2018; 2018():4396351. PubMed ID: 30035131
[TBL] [Abstract][Full Text] [Related]
16. Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context.
Baeyens A; Saadoun D; Billiard F; Rouers A; Grégoire S; Zaragoza B; Grinberg-Bleyer Y; Marodon G; Piaggio E; Salomon BL
J Immunol; 2015 Feb; 194(3):999-1010. PubMed ID: 25548233
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus.
Terrier B; Costedoat-Chalumeau N; Garrido M; Geri G; Rosenzwajg M; Musset L; Klatzmann D; Saadoun D; Cacoub P
J Rheumatol; 2012 Sep; 39(9):1819-28. PubMed ID: 22859347
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.
Graßhoff H; Comdühr S; Monne LR; Müller A; Lamprecht P; Riemekasten G; Humrich JY
Front Immunol; 2021; 12():648408. PubMed ID: 33868284
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases.
Xu L; Song X; Su L; Zheng Y; Li R; Sun J
Int Immunopharmacol; 2019 Jul; 72():322-329. PubMed ID: 31005777
[TBL] [Abstract][Full Text] [Related]
20. Modulation of T cell responses by IL-2 and IL-2 complexes.
Boyman O; Kolios AG; Raeber ME
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S54-7. PubMed ID: 26457438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
